A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

Inclusion Criteria:

* Voluntarily participate in the study and sign the informed consent.
* Age≥18 years.
* Subjects with relapsed or refractory lymphoma.
* Subjects with at least one measurable tumor lesion.
* ECOG 0-2.
* Life expectancy≥3 months.
* Adequate organ functions.

Exclusion Criteria:

* Subjects who had received anticancer therapy or radiotherapy within 21 days or 5 half-lives (whichever is shorter) before enrollment or received adoptive cellular immunotherapy within 12 weeks.
* Subjects who had received allogeneic hematopoietic stem cell transplantation or organ transplantation or received autologous hematopoietic stem cell transplantation within 3 months.
* Subjects with primary or secondary CNS lymphoma.
* History of another malignancy within 3 years before the first dose of investigational drug.
* History of active autoimmune diseases.
* Systemic immunosuppressive therapy within 2 weeks prior to the first dose of investigational drug.
* Subjects who experienced grade 3 or above immune-related adverse events (irAE) .
* Documented history of uncontrolled systemic diseases.
* Subjects who were allergic to any composition of investigational drug.
* Major surgery within 28 days prior to first dose of investigational drug.
* Subjects with active infection.
* Preexisting treatment related toxicity Grade ≥ 2 (except alopecia).
* Subjects with poor treatment compliance.
* Use of any investigational drug or device within 28 days prior to the first dose of investigational drug.
* Live vaccine was administered within 28 days prior to first dose of investigational drug.
* Pregnant or lactating women.